Abstract
Transient receptor potential vanilloid 6 (TRPV6) channels play an important role in intestinal Ca2+ transport. These channels undergo Ca2+-induced inactivation. Here we show that Ca2+ flowing through these channels activates phospholipase C (PLC) leading to the depletion of phosphatidylinositol 4,5-bisphosphate (PIP2) and formation of inositol 1,4,5-trisphosphate in TRPV6-expressing cells. PIP2 depletion was inhibited by the two structurally different PLC inhibitors 1-[6-[[17β-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione (U73122) and edelfosine. Ca2+-induced inactivation of TRPV6 was also prevented by the PLC inhibitors in whole-cell patch-clamp experiments. Ca2+ signals in TRPV6-expressing cells were transient upon restoration of extracellular Ca2+ but were rendered more sustained by the PLC inhibitors. Finally, intestinal Ca2+ transport in the everted duodenal sac assay was enhanced by edelfosine. These observations suggest that Ca2+-induced inactivation of TRPV6 limits intestinal Ca2+ absorption and raise the possibility that Ca2+ absorption can be enhanced pharmacologically by interfering with PLC activation.
Footnotes
-
This work was supported by the National Institutes of Health National Institute of Neurological Disorders and Stroke [Grant NS055159]; the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [Grant DK38961]; the National Institutes of Health National Institute on Aging [Grant AG297512]; the Alexander and Alexandrine Sinsheimer Foundation; and the University of Medicine and Dentistry of New Jersey Foundation.
-
ABBREVIATIONS: TRPV6, transient receptor potential vanilloid 6; TRPV5, transient receptor potential vanilloid 5; TRPM8, transient receptor potential melastatin 8; TRPM4, transient receptor potential melastatin 4; PLC, phospholipase C; PIP2, phosphatidylinositol 4,5-bisphosphate; GFP, green fluorescent protein; CFP, cyan fluorescent protein; YFP, yellow fluorescent protein; PH, pleckstrin homology; NDF, nominally divalent-free; FRET, fluorescence resonance energy transfer; IP3, inositol 1,4,5-trisphosphate; U73122, 1-[6-[[17β-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione; HEK, human embryonic kidney; DMSO, dimethyl sulfoxide; U73343, 1-[6-[[17β-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-2,5-pyrrolidine-dione.
- Received October 7, 2008.
- Accepted December 10, 2008.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|